HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intangible Benefits Are Influential In OTC Switch Decisions – CDER’s Ganley

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

Non-measurable benefits can tip the scales in the benefit/risk consideration of an OTC switch NDA, suggests Charles Ganley, director of CDER's Office of Drug Evaluation IV. One way to look at non-measurable benefits is how OTC ingredients "lower the threshold” for patient “misery” prior to seeking relief, he says.

You may also be interested in...



CDER Benefit/Risk Assessment Tool Has Room For OTC Considerations

A new benefit/risk framework for drug reviews currently being tested in FDA requires incremental considerations to apply to OTC reviews, a CDER official says. Former NDAC chairman Brass says FDA’s model is compatible with a separate OTC assessment framework developed for industry.

CHPA Quantifies OTCs’ Overall Value To Promote Expanded Access

Information from the CHPA-commissioned study could help improve policymakers’ understanding of the costs of making OTCs less available as well as the benefits of more Rx-to-OTC switches.

P&G Asks FDA To Make Prilosec The Standard For OTC PPI Claims

Procter & Gamble is asking FDA to develop class labeling for OTC proton pump inhibitors that would effectively preclude all products in the category from claiming greater efficacy than P&G's Prilosec OTC

Topics

Related Companies

UsernamePublicRestriction

Register

RS122967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel